MTNB — Matinas BioPharma Holdings, Inc.
$0.90
$-0.02 (-2.00%)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Market Cap
$881568.00
Forward P/E
-0.3x
52-Week Range
N/A
MTNB Price History
Revenue vs. Net Income
$0
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$15.9M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-202.1%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.5x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
19.9%
CapEx · FY2023
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+12.0%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
